A Multicentre, Long-term Safety, Efficacy, and Pharmacokinetics Study of Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation
Phase of Trial: Phase III
Latest Information Update: 04 Mar 2019
Price : $35 *
At a glance
- Drugs Lubiprostone (Primary)
- Indications Constipation
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sucampo Pharmaceuticals
- 05 Jun 2018 Results (n=419) presented at the Digestive Disease Week 2018.
- 19 Sep 2017 Status changed from active, no longer recruiting to completed.
- 23 Jul 2017 This study has been completed in Poland (End date:2017-05-01).